Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Licenses Nanopore Technology from Harvard to Develop 'Third Generation' Sequencer

NEW YORK (GenomeWeb News) - Sequenom said yesterday that it has exclusively licensed technology from Harvard University that it will use to develop a nanopore-based sequencing platform that will be faster and cheaper than currently available technologies.
 
The technology, which is able to detect a single strand of DNA as it passes through a nanopore, was developed by Amit Meller, an associate professor at Boston University’s Department of Biomedical Engineering. Meller invented the technology while at Harvard’s Rowland Institute.
 
Sequenom said it expects the technology to enable DNA sequencing, as well as whole-genome genotyping and RNA and epigenetic analysis.
 
Harry Stylli, CEO of Sequenom, said that the proposed system will be “complementary” to the company’s MassArray genotyping platform. "Near term we expect this nanopore technology to deliver large-scale genotyping solutions and long term we believe it has the potential to provide a commercially viable, rapid, sub-thousand dollar human genome sequencing solution," he said.
 
Financial terms of the license agreement include up-front fees, milestone payments, and royalties from product sales. Further details were not provided.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.